Latest News

After years of battling, Vertex and the U.K. reach a deal for cystic fibrosis medicines

After years of frustration, Vertex Pharmaceuticals struck a deal with the U.K. government to supply its cystic fibrosis medicines, capping an end to a dispute that had become a symbol of the growing clash between cash-strapped governments and drug makers over the rising prices for medicines.

The agreement covers all cystic fibrosis treatments sold by Vertex, including a new triple-combination therapy once it is licensed in the U.K. Pricing was not disclosed, but the deal includes a cost-effectiveness appraisal of its entire portfolio supported by real-world data, which will be completed by September 2021, and a “flexible contractual mechanism” that guarantees the medicines will remain available, according to this letter from the National Health Service in England to a Parliamentary committee.

Read the rest…

Source link

Related posts

Defective ATP13A2 gene can lead to Parkinson's disease, shows study


Genetic factors linked to obesity may lower metabolic risk


Medical News Today: What to know about tonsillectomy scabs


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy